Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyu-Pyo Kim

Showing results (151-160 of 217) with videos related to

Pageof 22
Sort By:
Cancer Research and Treatment|July 12, 2019
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaKyoungmin Lee, Kyunghye Bang, Changhoon Yoo, et al.
Human Pathology|September 28, 2018
High-grade precursor lesions can be used as surrogate markers to identify the epicenter of periampullary carcinomasByung-Kwan Jeong, You Na Sung, Sung Joo Kim, et al.
Hepatology (Baltimore, Md.)|April 18, 2023
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trialHyehyun Jeong, Kyu-Pyo Kim, Jae Ho Jeong, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2024
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa studyHyehyun Jeong, Bum Jun Kim, Choong-Kun Lee, et al.
Cancer Research and Treatment|January 16, 2018
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract CancerChanghoon Yoo, Boram Han, Hyeong Su Kim, et al.
Oncotarget|April 27, 2017
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaChanghoon Yoo, Jihoon Kang, Deokhoon Kim, et al.
Oncology|August 21, 2014
Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancerByeong Seok Sohn, Seong Joon Park, Jeong Eun Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 31, 2016
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal CancerJae Ho Jeong, Yong Sang Hong, Yangsoon Park, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2018
Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score-Matched AnalysisYoung Seob Shin, Jin-Hong Park, Sang Min Yoon, et al.
Clinical Therapeutics|November 19, 2008
Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I studyKyoung Soo Lim, Jung-Ryul Kim, Yun-Jung Choi, et al.
Pageof 22

Showing results (151-160 of 217) with videos related to

Sort By:
Pageof 22
Cancer Research and Treatment|July 12, 2019
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaKyoungmin Lee, Kyunghye Bang, Changhoon Yoo, et al.
Human Pathology|September 28, 2018
High-grade precursor lesions can be used as surrogate markers to identify the epicenter of periampullary carcinomasByung-Kwan Jeong, You Na Sung, Sung Joo Kim, et al.
Hepatology (Baltimore, Md.)|April 18, 2023
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trialHyehyun Jeong, Kyu-Pyo Kim, Jae Ho Jeong, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2024
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa studyHyehyun Jeong, Bum Jun Kim, Choong-Kun Lee, et al.
Cancer Research and Treatment|January 16, 2018
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract CancerChanghoon Yoo, Boram Han, Hyeong Su Kim, et al.
Oncotarget|April 27, 2017
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaChanghoon Yoo, Jihoon Kang, Deokhoon Kim, et al.
Oncology|August 21, 2014
Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancerByeong Seok Sohn, Seong Joon Park, Jeong Eun Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 31, 2016
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal CancerJae Ho Jeong, Yong Sang Hong, Yangsoon Park, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2018
Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score-Matched AnalysisYoung Seob Shin, Jin-Hong Park, Sang Min Yoon, et al.
Clinical Therapeutics|November 19, 2008
Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I studyKyoung Soo Lim, Jung-Ryul Kim, Yun-Jung Choi, et al.
Pageof 22